225Ac-DOTATATE is the alpha-labeled analogue of 90Y- and 177Lu-DOTATATE (Lutathera). This alpha-labeled analogue of a radiolabeled somatostatin was developed to be used in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) refractory to previous treatment with 177Lu-DOTATATE.
There are only a few articles available reporting about 225Ac-DOTATATE. By end of 2019, the center of Bad Berka, Germany, announced that they had already treated 25 different patients with this drug.
Target/Mechanism: Somatostatine receptors
Leading Emitter: alpha particle (α)